- Email: [email protected]
Effect of levalbuterol on exhaled nitric oxide (NO) levels in asthmatic subjects
S32 Abstracts
J ALLERGY CLIN IMMUNOL FEBRUARY 2004
SATURDAY 32
Effect of Levalbuterol on Exhaled Nitric Oxide (NO) Levels in Asthmatic Subjects
R. Otte1, D. Gentile2, B. Angelini2, J. Krahnke2, H. Richards2, J. Trecki2, W. Doyle1, D. Skoner2; 1Children’s Hospital of Pittsburgh, Pittsburgh, PA, 2Allegheny General Hospital, Pittsburgh, PA. RATIONALE: Elevations of exhaled NO have been reported in
patients with asthma. Laboratory studies suggest that levalbuterol possesses anti-inflammatory properties. The objective of this study was to evaluate the effect of levalbuterol versus placebo on exhaled NO levels in subjects with asthma. METHODS: A total of 42 adults, aged 18 to 37 years were enrolled in this parallel, double-blind, placebo-controlled study. Twenty-eight (67%) were female and 10 (24%) were African American. All subjects had a history of asthma and an FEV1 ≥60% at enrollment. Subjects received either nebulized placebo or levalbuterol 1.25 mg q 8 hours during a 2 week treatment period. Exhaled NO levels were measured at the end of 2 week run-in, 2 week treatment, and 2 week wash-out periods (sessions 2, 3 and 4, respectively). RESULTS: The majority of subjects had mild asthma and were not treated with inhaled corticosteroids. There were no significant effects of either treatment on NO levels at any of the sessions. Mean (± STD) levels for sessions 2, 3, and 4 were 1.40 ± 0.37, 1.34 ± 0.40, and 1.30 ± 0.38 for the active group, and 1.30 ± 0.25, 1.33 ± 0.26, 1.26 ± 0.18 for the placebo group. CONCLUSIONS: These results do not support a role for levalbuterol in reducing exhaled NO levels in subjects with mild asthma. Future studies should explore the effect of this agent on NO levels and other markers of inflammation in subjects with more severe disease. Funding: Sepracor
Abstracts S33
SATURDAY
J ALLERGY CLIN IMMUNOL VOLUME 113, NUMBER 2
J ALLERGY CLIN IMMUNOL FEBRUARY 2004
SATURDAY 32
Effect of Levalbuterol on Exhaled Nitric Oxide (NO) Levels in Asthmatic Subjects
R. Otte1, D. Gentile2, B. Angelini2, J. Krahnke2, H. Richards2, J. Trecki2, W. Doyle1, D. Skoner2; 1Children’s Hospital of Pittsburgh, Pittsburgh, PA, 2Allegheny General Hospital, Pittsburgh, PA. RATIONALE: Elevations of exhaled NO have been reported in
patients with asthma. Laboratory studies suggest that levalbuterol possesses anti-inflammatory properties. The objective of this study was to evaluate the effect of levalbuterol versus placebo on exhaled NO levels in subjects with asthma. METHODS: A total of 42 adults, aged 18 to 37 years were enrolled in this parallel, double-blind, placebo-controlled study. Twenty-eight (67%) were female and 10 (24%) were African American. All subjects had a history of asthma and an FEV1 ≥60% at enrollment. Subjects received either nebulized placebo or levalbuterol 1.25 mg q 8 hours during a 2 week treatment period. Exhaled NO levels were measured at the end of 2 week run-in, 2 week treatment, and 2 week wash-out periods (sessions 2, 3 and 4, respectively). RESULTS: The majority of subjects had mild asthma and were not treated with inhaled corticosteroids. There were no significant effects of either treatment on NO levels at any of the sessions. Mean (± STD) levels for sessions 2, 3, and 4 were 1.40 ± 0.37, 1.34 ± 0.40, and 1.30 ± 0.38 for the active group, and 1.30 ± 0.25, 1.33 ± 0.26, 1.26 ± 0.18 for the placebo group. CONCLUSIONS: These results do not support a role for levalbuterol in reducing exhaled NO levels in subjects with mild asthma. Future studies should explore the effect of this agent on NO levels and other markers of inflammation in subjects with more severe disease. Funding: Sepracor
Abstracts S33
SATURDAY
J ALLERGY CLIN IMMUNOL VOLUME 113, NUMBER 2